Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy

Barca, Cristina; Griessinger, Christoph M.; Faust, Andreas; Depke, Dominic; Essler, Markus; Windhorst, Albert D.; Devoogdt, Nick; Brindle, Kevin M.; Schäfers, Michael; Zinnhardt, Bastian; Jacobs, Andréas H.

doi:10.3390/ph15010013

Cited by 38 publications

(22 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…124 I finds, however, its application, collectively with 131 I, as a part of a theranostic pair [ 54 ]. Such pairs, formed of the similar and matching radionuclides, better serve diagnostic purposes by lowering radiation burden and achieving better image quality [ 55 ].…”

Section: Discussionmentioning

confidence: 99%

Efficiency of 124I radioisotope production from natural and enriched tellurium dioxide using 124Te(p,xn)124I reaction

et al. 2022

View full text Add to dashboard Cite

Background 124I Iodine (T$$_{1/2}$$ 1 / 2 = 4.18 d) is the only long-life positron emitter radioisotope of iodine that may be used for both imaging and therapy as well as for 131I dosimetry. Its physical characteristics permits taking advantages of the higher Positron Emission Tomography (PET) image quality, whereas the availability of new molecules to be targeted with 124I makes it a novel innovative radiotracer probe for a specific molecular targeting. Results In this study Monte Carlo and SRIM/TRIM modelling was applied to predict the nuclear parameters of the 124I production process in a small medical cyclotron IBA 18/9 Cyclone. The simulation production yields for 124I and the polluting radioisotopes were calculated for the natural and enriched 124TeO2 + Al2O3 solid targets irradiated with 14.8 MeV protons. The proton beam was degraded energetically from 18 MeV with 0.2 mm Havar foil. The 124Te(p,xn)124I reactions were taken into account in the simulations. The optimal thickness of the target material was calculated using the SRIM/TRIM and Geant4 codes. The results of the simulations were compared with the experimental data obtained for the natural TeO2 +Al2O3 target. The dry distillation technique of the 124-iodine was applied. Conclusions The experimental efficiency for the natural Te target was better than 41% with an average thick target (>0.8 mm) yield of 1.32 MBq/μAh. Joining the Monte Carlo and experimental approaches makes it possible to optimize the methodology for the 124I production from the expensive Te enriched targets.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficiency of 124I radioisotope production from natural and enriched tellurium dioxide using 124Te(p,xn)124I reaction

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The pharmacokinetics, pharmacodynamics, and biodistribution patterns of radiopharmaceuticals are all affected by changes in the linker and chelator regions. Several nucleotides such as 47 Sc, 90 Y, 131 I, 166 Ho, 177 Lu, 188 Re, and 213 Bi will be the most regularly manufactured radionuclides because of their capacity for theranostics purposes (for diagnosis and therapy at once) [ 228 ]. Development of a strategy for building radiopharmaceuticals using a small molecule [ 229 ], amino acid [ 230 ], and peptide labeling [ 116 ] and using a macro-chelating agent for radiometal labeling can be used in a strategy to construct radiopharmaceuticals with improved stability [ 108 ].…”

Section: Impact To the Future Trend Of Radiopharmaceuticalsmentioning

confidence: 99%

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker

et al. 2022

View full text Add to dashboard Cite

Therapeutic radiopharmaceuticals have been researched extensively in the last decade as a result of the growing research interest in personalized medicine to improve diagnostic accuracy and intensify intensive therapy while limiting side effects. Radiometal-based drugs are of substantial interest because of their greater versatility for clinical translation compared to non-metal radionuclides. This paper comprehensively discusses various components commonly used as chemical scaffolds to build radiopharmaceutical agents, i.e., radionuclides, pharmacokinetic-modifying linkers, and chelators, whose characteristics are explained and can be used as a guide for the researcher.

show abstract

“…NPs can be labeled with several radionuclides and have been proposed as innovative tools for imaging with single-photon emission computerized tomography (SPECT) and positron emission tomography (PET) and enhanced radioisotope therapy for several cancer types with limited toxicity [195].…”

Section: In Vitro and In Vivo Tracking Of Np Deliverymentioning

confidence: 99%

“…Advantageous strategies for simultaneous diagnostics and therapy are also being characterized. In this context, a promising strategy is the pairing of radionuclides of different elements [195]. As an example, 68Ga for PET imaging and 177Lu as β-emitter for a therapy couple have been investigated as a radiopharmaceutical tool to face prostate [181] colon [182], lymph node [183][184][185] and glioblastoma [186] cancers.…”

Section: In Vitro and In Vivo Tracking Of Np Deliverymentioning

confidence: 99%

Nanotechnology-Assisted Cell Tracking

et al. 2022

View full text Add to dashboard Cite

The usefulness of nanoparticles (NPs) in the diagnostic and/or therapeutic sector is derived from their aptitude for navigating intra- and extracellular barriers successfully and to be spatiotemporally targeted. In this context, the optimization of NP delivery platforms is technologically related to the exploitation of the mechanisms involved in the NP–cell interaction. This review provides a detailed overview of the available technologies focusing on cell–NP interaction/detection by describing their applications in the fields of cancer and regenerative medicine. Specifically, a literature survey has been performed to analyze the key nanocarrier-impacting elements, such as NP typology and functionalization, the ability to tune cell interaction mechanisms under in vitro and in vivo conditions by framing, and at the same time, the imaging devices supporting NP delivery assessment, and consideration of their specificity and sensitivity. Although the large amount of literature information on the designs and applications of cell membrane-coated NPs has reached the extent at which it could be considered a mature branch of nanomedicine ready to be translated to the clinic, the technology applied to the biomimetic functionalization strategy of the design of NPs for directing cell labelling and intracellular retention appears less advanced. These approaches, if properly scaled up, will present diverse biomedical applications and make a positive impact on human health.

show abstract

Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy

Cited by 38 publications

References 125 publications

Efficiency of 124I radioisotope production from natural and enriched tellurium dioxide using 124Te(p,xn)124I reaction

Efficiency of 124I radioisotope production from natural and enriched tellurium dioxide using 124Te(p,xn)124I reaction

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker

Nanotechnology-Assisted Cell Tracking

Contact Info

Product

Resources

About